In addition to the robust in vivo efficacy of PTPRZ1-TCR-T, we found universal targeting of HLA-A*02+ primary glioblastoma cell lines and malignant cells in IPTOs with a preference for stem-like SCCs and AC-like tumor cells. Here, PTPRZ1 is linked to neoplasm.